Duration of post-vaccination immunity against yellow fever in adults  by unknown
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Introduction:  Available  scientiﬁc  evidence  to recommend  or to advise  against  booster  doses  of  yellow
fever vaccine  (YFV)  is  inconclusive.  A study  to estimate  the  seropositivity  rate  and  geometric  mean  titres
(GMT)  of  adults  with  varied  times  of  vaccination  was aimed  to provide  elements  to  revise  the  need  and
the  timing  of  revaccination.
Methods: Adults  from  the  cities  of Rio  de  Janeiro  and Alfenas  located  in  non-endemic  areas  in the  Southeast
of  Brazil,  who  had  one  dose  of  YFV,  were  tested  for YF neutralising  antibodies  and  dengue  IgG. Time  (in
years)  since  vaccination  was  based  on  immunisation  cards  and  other  reliable  records.
Results:  From  2011  to  2012  we recruited  691  subjects  (73%  males),  aged  18–83 years.  Time  since  vacci-
nation  ranged  from  30 days  to 18  years.  Seropositivity  rates  (95%C.I.)  and  GMT  (International  Units/mL;
95%C.I.)  decreased  with  time  since  vaccination:  93%  (88–96%),  8.8  (7.0–10.9)  IU/mL  for  newly  vaccinated;
94%  (88–97),  3.0  (2.5–3.6)  IU/mL  after  1–4 years;  83%  (74–90),  2.2 (1.7–2.8)  IU/mL  after  5–9 years;  76%
(68–83),  1.7  (1.4–2.0)  IU/mL  after  10–11 years;  and  85%  (80–90),  2.1  (1.7–2.5)  IU/mL  after  12  years  or
more.  YF  seropositivity  rates  were  not  affected  by  previous  dengue  infection.
Conclusions:  Eventhough  serological  correlates  of protection  for yellow  fever  are  unknown,  seronegativity
in vaccinated  subjects  may  indicate  primary  immunisation  failure,  or  waning  of  immunity  to  levels  below
the  protection  threshold.  Immunogenicity  of  YFV  under  routine  conditions  of immunisation  services  is
likely to be lower  than  in  controlled  studies.  Moreover,  infants  and  toddlers,  who  comprise  the  main
target  group  in  YF endemic  regions,  and  populations  with  high  HIV  infection  rates,  respond  to YFV  with
lower  antibody  levels.  In  those  settings  one  booster  dose,  preferably  sooner  than  currently  recommended,
seems  to be necessary  to ensure  longer  protection  for all  vaccinees.
© 2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
Yellow fever is an acute arboviral disease with clinical presen-
ations that include mild forms with a sudden onset of febrile
ymptoms and severe forms with over 30% lethality, and also
symptomatic infections [1]. Yellow fever is one of the diseases
equiring immediate report to the World Health Organization
WHO) under International Health Regulations [2].
In Brazil, most cases of yellow fever occur among adult males
onducting occupational, tourism, or leisure activities in forested
reas, where they become exposed to infected mosquitoes, mainly
he wild species Haemagogus janthinomys. Although disease trans-
ission in urban areas have not been reported in Brazil since 1942,
poradic outbreaks of yellow fever transmitted by jungle vectors
n the southern and southeastern regions of the country, close to
rban zones where Aedes aegypti is abundant, poses a threat of
e-urbanisation of the disease [3].
1 The research group is described in Appendix A.
ttp://dx.doi.org/10.1016/j.vaccine.2014.07.021
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unThere is no speciﬁc treatment for yellow fever. Disease preven-
tion relies on current commercially available vaccines, which are
highly immunogenic and safe. Immunisation is recommended to
unvaccinated residents and travellers to and from at-risk areas,
aged ≥9 months [3,4].
Despite the lack of efﬁcacy studies on yellow fever vaccines, vac-
cine effectiveness is evidenced by the dramatic reduction of disease
incidence following mass vaccination. The duration of vaccine-
induced immunity in primo-vaccinated adults appears to last for
decades [5]. Previous recommendations [6] of revaccination have
been revised by WHO  experts in 2013 [5] and a systematic review of
scientiﬁc evidence available until June 2012 [7]. The International
Health Regulations have been ammended in May  2014 to stipulate
that a single dose of the yellow fever vaccine is valid for the duration
of the vaccinee’s life [2].
Data on the long-term immunity induced by yellow fever
vaccine, which should guide vaccination policy are still scarce.
Therefore, this study aimed to assess the level of neutralising
antibodies persisting after years of primovaccination against yel-
low fever in adults. Moreover, the study evaluated the immune
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
4 2014)
s
t
h
2
t
y
a
g
r
s
n
a
t
t
s
b
t
s
d
f
d
c
M
m
h
1
b
t
m
s
r
a
v
w
a
b
t
t
m
t
c
f
e
l
t
g
c
l
s
g
w
h
a
C
2
c978 Vaccine 32 (
tatus of adults over 1 year post-vaccination compared with
hose at 30 days post-vaccination using neutralising antibodies as
umoral immune response biomarkers.
. Methods
This cross-sectional study was designed to assess and compare
he rate of seropositivity and the geometric mean titres (GMT) of
ellow fever neutralising antibodies persisting in primo-vaccinated
dults. The time since vaccination was grouped in arbitrary cate-
ories to determine the length of time that it takes for the immune
esponse to decline and warrant the need for revaccination. Study
ubjects were grouped according to the length of time since vacci-
ation as follows: 30–45 days, 1–4 years, 5–9 years, 10–11 years,
nd 12 years or more. In the 30–45 days vaccination subgroup,
he presence of neutralising antibodies was also assessed prior
o immunisation. The immune response in this newly vaccinated
ubgroup provided the reference to assess the variation of anti-
ody levels over time. For the comparison subgroups, 1 year was
hought to be the minimum time since vaccination, to disclose
ubstantial decline antibody titres. In addition, the effects of anti-
engue IgG antibodies on the humoral immune status of yellow
ever-vaccinated adults were also evaluated.
The study population comprised adult volunteers of both gen-
ers serving in the Army in the city of Rio de Janeiro, in addition to
ivilian volunteers from the “Oswaldo Cruz” Foundation (FIOCRUZ;
anguinhos campus, Rio de Janeiro) and from health centres in the
unicipality of Alfenas, state of Minas Gerais. All subjects either
ad received a single dose of the yellow fever vaccine 17DD at least
 year before (conﬁrmed in immunisation records) or had never
een vaccinated (Fig. 1). Rio de Janeiro residents are advised to take
he yellow fever vaccine only if they travel to endemic areas. The
unicipality of Alfenas is located in Minas Gerais, which is a large
tate in southeast Brazil where vaccination against yellow fever is
ecommended at the age of 9 months. In the Alfenas region, there
re no recorded cases of yellow fever. In Brazil, infections by ﬂa-
iviruses other than dengue and yellow fever have been reported,
ith minor public health signiﬁcance.
Aliquots (5 mL)  of peripheral blood were collected to measure
nti-yellow fever neutralising antibodies and anti-dengue IgG anti-
odies. Vaccinated subjects were divided into subgroups according
o the time elapsed since their last vaccination and were submit-
ed to serological tests to quantify yellow fever antibody titres. A
ilitary subgroup with no history of yellow fever vaccination was
ested for yellow fever antibodies immediately before routine vac-
ination required for military personnel involved in missions in the
orest. It followed standard immunisation procedures for the gen-
ral population, which have not undergone major changes in the
ast decades. The procedures followed in this study were limited
o the application of questionnaires inquiring about sociodemo-
raphic data and personal medical history, in addition to blood
ollection for serological tests to determine the maximum antibody
evels that the vaccination could achieve. This newly vaccinated
ubgroup provided the reference for comparison with other sub-
roups who were vaccinated for longer periods.
Specimens were collected after a signed informed consent
as obtained from each participant, and the data collected were
andled so as to protect conﬁdentiality. The study protocol was
pproved by the Research Ethics Committee of the Evandro Chagas
linical Research Institute at FIOCRUZ (Opinion No. 040/2011)..1. Eligibility criteria
Subjects with proof of vaccination (in vaccination card or medi-
al records) and who agreed to the terms of the study were eligible 4977–4984
to participate in the study. Exclusion criteria included the follow-
ing: contraindications for yellow fever vaccine (e.g., pregnancy,
permanent or transient immunosuppression, severe adverse reac-
tions following previous vaccination, and severe allergy to chicken
eggs), individuals who  reported 2 or more previous vaccine doses
(even if proof of vaccination could not be provided), lack of proof
of prior vaccination, and residence in or travel to risk areas (which
have been deﬁned by the Health Surveillance Department of the
Ministry of Health) until the time of the study.
The rationale for inclusion of subjects with a documented single
dose of yellow fever vaccine and no potential exposure to nat-
ural infections was  to avoid interference of booster on antibody
levels induced by one dose. Cases with uncertain potential expo-
sure to infection were not included. In addition, military personnel
who participated in missions to endemic areas or who  had been
immunised more than once were excluded from the study.
2.2. Laboratory tests
The yellow fever neutralising antibody titres were quantiﬁed by
PRNT50 using 20 L of heat inactivated (56 ◦C for 30 min) serum
as described by Simões and colleagues [8] in the Laboratory of
Viral Technology of Bio-Manguinhos (LATEV/BIO, in Rio de Janeiro).
In each set of tests, a standard serum prepared in house was
included as positive control (called M7/100). This serum from Rhe-
sus monkeys (Macaca mulatta) vaccinated against YF had been
calibrated against an international reference serum from WHO
and was known to contain 1115 IU/mL. Antibody concentration
in IU/mL was calculated relative to the antibody content in the
international reference (quotient of 1115 IU/mL and the dilution
corresponding to the 50% endpoint of the reference is multiplied
by the dilution equivalent to the 50% of each serum sample).
Yellow fever antibody titres (in IU/mL) were classiﬁed as fol-
lows: titres ≥2.9 log10 IU/mL or reciprocal of the dilution ≥50
indicated positive serology; titres <2.5 log10 IU/mL or reciprocal
of the dilution <5 indicated negative serology; titres ≥ 2.5 and
<2.9 log10 IU/mL or reciprocal of the dilution ≥5 and <50 indicated
undetermined serology.
The serum samples were also tested for the presence of IgG by
ELISA to conﬁrm the presence of anti-yellow fever antibodies in sera
from vaccinated subjects according to previously described meth-
ods [9]. Serological tests (IgG) for dengue were performed at the
Flavivirus Laboratory of the Oswaldo Cruz Institute (Rio de Janeiro)
using PANBIO dengue IgG indirect Elisa (Brisbane, Australia) [10].
Dengue is a ﬂavivirus with widespread circulation in Brazil. Neu-
tralising antibody response to YF vaccine is highly speciﬁc with no
or low-titre antibodies to other ﬂavivirus, but evidence for interfer-
ence by naturally acquired heterologous ﬂavivirus immunity with
17D vaccine in humans is conﬂicting [11].
2.3. Statistical analysis
The response variable of interest was  the serum neutralising
antibody titres (in IU/mL), which were converted to log10 values
and categorised. The co-variables of interest were age (in years),
gender, presence of anti-dengue virus antibodies, prior vaccina-
tion, history of severe illness (hospitalisation, disease sequelae, and
disability), comorbidity and medications used at the time of blood
collection. The rate of seropositivity and the geometric mean anti-
body titres, along with the corresponding 95% conﬁdence intervals
(CI), were estimated for each subgroup of time since vaccination.
In the multivariate analysis, the immune response (indicated by
log10 of titres in the multiple regression model and seropositivity
in the logistic regression model) was modelled as a function of the
time (in months) elapsed since vaccination as a continuous variable
and categories: 30–45 days, 1–9 years, 10–11 years, and ≥12 years
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Further eligibility assessment (n=721) 
Excluded  (n=30): 
seropositive before  vaccination  (n=15); 
previous vaccination < 1 year (n=6); 
missing proof of vaccination (=2 ); 
failed to attend blood collection (n=4); 
travelled to  ende mic areas  (n=1); 
previous 2 doses of vaccine (n=2) 
Analysed  (n=125) 
  Excluded from analysis with seropositive  
or inconclusive pre-vaccination serology 
n=40);
Pre-vaccination serolo gical test (n=1 65)
No history  of previous  vaccination  (n=165) 
Serological tests  (n=526) 
History of single dose (n=526) 
 Time since previous vaccination: 
  1 – 4 years       (n=114) 
  5 – 9 years       (n=  83)     
  10 – 11 years   (n=138) 
 12+ years (n=1 91)
Analysed (n=526 )
Serological test  30-45  days  after 
vaccination  (n=165) 
Yellow fever vaccine  (n=165 )
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fter primo-vaccination (categories 1–4 and 5–9 years were col-
apsed for multivariate analysis). The co-variables included in the
odel were age, gender, city of residence, and serological status
or dengue. Statistical analysis was performed using the software
PSS® (SPSS Inc., Chicago, IL) and WINPEPI [12].
. Results
The study group consisted of a non-random sample of 721 adult
olunteers, which included military personnel from 7 Army units
ocated in the city of Rio de Janeiro (50.7%), and civilians from
he Manguinhos campus at FIOCRUZ in Rio de Janeiro (16%) and
rom health centres in Alfenas, Minas Gerais (33.3%). Volunteers
ere recruited between August 2011 and July 2012. The recruit-
ent sites were selected based on expected numbers of eligible
ubjects.
Of the 721 volunteers, 691 (95.8%) met  all eligibility criteria and
ere included in the analysis (Fig. 1). The eligible volunteers were
redominantly male (73.4%), aged 18–83 years, and the time since
accination ranged from 30 days to 18 years. In the newly vacci-
ated subgroup all subjects were male, aged 18–30 years, and the
ime since vaccination ranged from 30 to 45 days (data not shown).
ubjects aged 31–59 years had that highest proportion with 12
ears or more of vaccination, whereas most volunteers 60 years
nd older had been vaccinated 5–9 years before (Table 1).
In the newly vaccinated subgroup, the levels of neutralising
ntibodies prior to vaccination indicated that 10 subjects were monitoring of the volunteers.
seropositive for yellow fever, whereas 30 subjects had neutralising
antibody titre ≥2.5 and <2.9 log10 IU/mL. The latter were excluded
from the analysis as previous vaccination could not be ruled out
in individuals with borderline titres (Fig. 1). Their results were
disregarded to ensure the reference group contained only primo-
vaccinated subjects. Post-vaccination seropositivity among the 40
subjects excluded because of yellow fever high or borderline titres
before vaccination was 89.7%, whereas for those seronegative it was
93.7%.
As shown in Table 2, approximately 93% of volunteers
in the reference group became seropositive after vaccination.
The percentage of subjects with neutralising antibody titres
≥2.9 log10 IU/mL decreased gradually from 1–4 years up to
10–11 years post-vaccination. However, there was an unexpected
increase in the proportion of seropositive subjects in the subgroup
vaccinated for ≥12 years (Table 2). The distribution of antibody
titres according to the elapsed time since vaccination and the cor-
responding GMT  showed higher titres in newly vaccinated subjects
(up to 45 days) decreasing sharply in 1–4 years and slightly in 10–11
years, and followed by an unexpected slight increase in subjects at
≥12 years post-vaccination (Fig. 2 and Table 3).
The decreasing trend in antibody titres with the time since vac-
cination appeared strongly modiﬁed by age as the data showing
a signiﬁcant decline in antibody titres after one year were avail-
able only for 18–30-year-old subjects (Fig. 3). An increasing trend
in the mean titres across age groups was  disclosed in volunteers
with 10–11 years and ≥12 years post-vaccination.
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Table 1
Distribution of subjects according to the time since vaccination by age groups (in years).
Time since vaccination Age (years)
18–30 31–59 ≥60 Total
N % N % N % N %
30–45 days 165 56.9 0 0.0 0 0.0 165 23.9
1–4  years 67 23.1 46 13.4 1 1.8 114 16.5
5–9  years 20 6.9 32 9.3 31 54.4 83 12.0
10–11  years 6 2.1 128 37.2 4 7.0 138 20.0
≥12  years 32 11.0 138 40.1 21 36.8 191 27.6
Total  290 100 344 100 57 100 691 100
Table 2
Neutralising antibodies titres as assessed by PRNT according to the time since vaccination.
Time since vaccination Antibody titres (log10 IU/mL)a
<2.50 2.50–2.89 ≥2.90 Total
N % N % N % N %
30–45 days 3 2.4 5 4.0 117 93.6 125 100
1–4  years 1 0.9 6 5.3 107 93.9 114 100
5–9  years 5 6.0 9 10.8 69 83.1 83 100
10–11  years 11 8.0 22 15.9 105 76.1 138 100
≥12  years 11 5.8 17 8.9 163 85.3 191 100
w
a
t
f
i
(
sTotal  31 4.8 59 
a Antibody titres ≥2.9 log10 IU/mL were considered seropositive.
The percentage of subjects with anti-dengue IgG titres > 1:40
as 61.9%, overall, and 89.0% among subjects from Rio de Janeiro
nd 13.7% for Alfenas residents. There was no apparent correla-
ion between the immunological statuses for dengue and yellow
ever, as the rate of yellow fever seropositives by PRNT was  sim-
lar to that of seropositives and seronegatives (IgG) for dengue
Table 4). The distribution of post-vaccination titres was somewhat
kewed for higher values in dengue-IgG positive subjects, whose
Fig. 2. Frequency distribution of antibody titres (log10 IU/mL) as 9.1 561 86.2 651 100
yellow fever antibody GMT  was 3118 IU/mL (95%C.I.: 2756–3527),
whereas dengue IgG negative subjects had a GMT 2445 IU/mL (95%
C.I.: 2094–2860). However, the comparability of dengue IgG posi-
tive and negative subgroups was  confounded by age and time since
vaccination.
In the multivariate analysis, only the elapsed time since vacci-
nation had a signiﬁcant correlation with the antibody titres (using
the multiple regression model) and with positive serology for
assessed by PRNT according to the time since vaccination.a
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Fig. 3. Mean values at 95% CI of neutralising antibody titres (log10 IU/mL) a
Table 3
Geometric mean antibody titres at 95% CI (IU/mL) according to the time since
vaccination.
Time since vaccination (years) N GMTa LLb ULc
30–45 days 125 8762.8 7042.6 10903.1
1–4  years 114 3007.5 2535.7 3567.8
5–9  years 83 2194.8 1725.4 2791.3
10–11 years 138 1661.9 1362.4 2026.7
≥12  years 191 2123.1 1787.0 2522.5
Total 651 2824.6 2558.7 3118.1
y
t
b
i
t
4
t
r
t
T
Pa GMT: geometric mean titres.
b LL: lower limit of the 95% conﬁdence interval.
c UL: upper limit of the 95% conﬁdence interval.
ellow fever (using the logistic regression model). Consistent with
he effects of the elapsed time since vaccination and age on anti-
ody titres shown in Fig. 3, the interaction term of those two
ndependent variables in the multiple regression model was sta-
istically signiﬁcant (p < 0.001).
. DiscussionThe duration of immunity after yellow fever vaccination is
he main parameter to determine the need and timing for
evaccinations, which have important implications in immunisa-
ion programmes for residents and travellers to and from endemic
able 4
ercentage of subjects according to the presence of IgG antibodies against dengue virus a
Antibody titres against yellow fever (log10 IU/mL) Anti-dengue virus IgG antib
Inconclusive 
N % 
<2.50 1 12.5 
2.50–2.89 0 0.0 
≥2.90 7 87.5 
Total  8 100 gainst yellow fever according to the time since vaccination and age.
areas, and for laboratory personnel who  handle vaccine or sylvatic
virus strains. The yellow fever vaccine is the only attenuated virus
vaccine in which the recommendation for revaccination is every
10 years, indeﬁnitely, without sound scientiﬁc basis. The recom-
mendation of a single vaccine dose for life is still controversial, and
should probably await more convincing scientiﬁc evidence [13,14]
before implementation. An alternative to consider is that, similarly
to other vaccines, primary and secondary yellow fever vaccine fail-
ures might occur and should discourage both the recommendation
of a single dose for life and the need to wait 10 years for revaccina-
tion. In this study, the percentage of seropositive subjects and the
GMTs of anti-yellow fever antibodies were substantially lower at 5
years post-vaccination when compared with the newly vaccinated
subjects (up to 45 days), and continued decreasing, albeit slightly,
up to 10–11 years post-vaccination. The rate of seropositivity in the
newly vaccinated subjects (93.6% with titres ≥2.9 log10 IU/mL) was
slightly lower than in other studies involving adults: 96.0–98.0%
[15,16].
A decreasing trend in neutralising antibody titres had been
reported in 1948 in Brazilian vaccinees of various age groups,
among whom 87% and 72% were reactive (intraperitoneal pro-
tection test in adult mice) at 2 and 6 years post-vaccination,
respectively) [17]. A pronounced decrease in the ﬁrst 5 years
post-vaccination was  also shown in 1999 in German vaccinees
10–79 years old [18]. Among those volunteers vaccinated for
11–38 years, 25.5% had neutralising antibodies (PRNT) ≤1:10. In
nd the presence of neutralising antibody titres against yellow fever.
odies
Negative Positive Total
N % N % N %
12 5.0 18 4.5 31 4.8
21 8.8 38 9.4 59 9.1
207 86.3 347 86.1 561 86.2
240 100 403 100 651 100
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008, Colombian volunteers aged 1–76 years were shown to have
heir seropositivity rates (titres > 1:10, PRNT) decreased from 97.1%
mong subjects that had been vaccinated for less than 1 year to
8.4% with 4 or more years post-vaccination [16]. Conversely, 95%
f subjects vaccinated at the Pasteur Institute for over 10 years had
ntibody titres detected by PRNT [19]. Volunteers were over 60
ears of age and vaccination time was inferred for some of them,
ithout mention of the number of doses.
A study performed in a randomly selected population 16–83
ears old, based on travel vaccination records of residents in Recife,
razil, where there is no yellow fever transmission, reported that
he mean neutralising antibody titres by PRNT were higher in 20
ubjects vaccinated for 5 years than in 20 subjects vaccinated for
0 years. All subjects were seropositive (PRNT), whereas 60% and
5%, respectively, were IgG positive [20]. However, it was  not men-
ioned the possibility that the subjects might have travelled to
egions susceptible to disease transmission (with potential for nat-
ral boosting) or might have received more than a single vaccine
ose.
The higher seropositivity rate in the group immunised for ≥12
ears, compared to the group vaccinated for 10–11 years could pos-
ibly be due to differences in the vaccine and to non-recorded or
on-reported multiple vaccination, as it is plausible that revac-
ination is more likely in individuals eligible after 10 years of
he previous dose. Most likely, these unreported vaccinations also
ccurred in the 10- to 11-year vaccination subgroup ceasing anti-
ody decay in some individuals and leading to overestimated
eropositive rates attributable to a single dose. That observation
isclosed a limitation of this study and illustrated the challenge of
scertaining the number of vaccine doses and time since immun-
sation in adults. Even more challenging was the characterisation of
otential for exposure to natural infection, which led to exclusion
f volunteers.
In addition to selecting subjects not likely to be exposed to
atural infections, to ensure that yellow fever seropositivity was
xplained by a single reported dose of the vaccine was  a major
hallenge in this study. In a study used as reference for in the single
accination recommendation by the WHO  [21], 9 of 24 volunteers
ere revaccinated. However, other reference studies have not clar-
ﬁed whether revaccination was considered when assessing the
uration of immunity [7].
Methodological differences across studies, such as, the vaccine
tself, different substrains of vaccine virus, vaccination procedures,
olunteer proﬁle, serological test methods and seropositity criteria,
re important factors that may  have contributed to the discrep-
ncy of results previously reported. In general, these studies were
ross-sectional and the comparison across subgroups with distinct
lapsed times since vaccination disregarded variations in immun-
sation procedures and in the vaccine potency over time. In Brazil,
accination against yellow fever in routine health care has used
he same vaccine and similar procedures for several decades, thus
avouring the comparability of results from the different cohorts
epresented in the present study. On the other hand, the represen-
ativeness of non-randomly selected volunteers may  be limited.
The selection of volunteers for this study entailed the exclusion
f those who resided or remained in geographical areas suscepti-
le to yellow fever transmission so that natural booster infections
ould not confound the experimental results. Even in areas, such
s Alfenas, where vaccination is recommended for residents, yel-
ow fever cases have not occurred in humans for many decades.
n addition, epidemiological surveillance data have indicated the
ack of circulation of sylvatic virus strains in non-human primates
unpublished data available in worksheets from Minas Gerais State
ealth Secretary).
In this as in other studies [20,22], yellow fever seropositivity
ssessed by PRNT did not appear to have been inﬂated by prior 4977–4984
exposure to dengue infection. It seemed more likely that dengue
IgG seropositivity (Elisa) could be partly attributed to persisting
neutralising antibodies against yellow fever. In contrast, higher
neutralising capacity for the yellow fever virus in subjects with
anti-dengue IgG antibodies has been reported, and hypothesised
that subgroups with positive serology for dengue could develop
cross-reactions with anti-yellow fever antibodies [16].
In 2013, the WHO  Strategic Advisory Group of Experts (SAGE)
announced that a single dose of the yellow fever vaccine provides
life-long immunity and that revaccination every 10 years is not
necessary for people who  live in or travel to risk areas [4]. This
new guideline was  based on surveillance data indicating that vac-
cination failures are extremely rare and do not cluster as time
increases after immunisations [4]. However, the known limitations
in the surveillance of yellow fever cases and in the management of
vaccination records, particularly in adults, suggest that data on vac-
cination failure are underestimated [14]. The rarity of vaccination
failure could also be partly explained by the revaccination require-
ment in immunisation programmes and prior to travel to endemic
areas. However, the absence of yellow fever cases in vaccinated
travellers does not appear to be a good indicator of the duration
of immunity, considering that potential natural exposures, which
warrant recommendation for vaccination, can impair the assess-
ment of the long-term effects of vaccination.
WHO’s recent recommendations have also generated contro-
versies because the serological methods used have varied over the
many decades during which the studies that served as the basis
for the recommendations were performed [14]. In addition, the
PRNT method that determines neutralising antibody titres, which is
considered the best available measure of seroprotection following
vaccination, has exhibited considerable heterogeneity and allows
only limited comparability between results [14].
A review exploring the scientiﬁc evidence for a change in the
vaccination recommendation proposed by the WHO  [7] appears
to disregard the possibility that seronegative subjects may  have
been a result of primary or secondary failures of the vaccine. In
fact, the high levels of vaccine immunogenicity in clinical studies
under controlled immunisation conditions in selected groups may
not be reproduced in routine immunisation programmes. These
are generally affected by problems related to vaccine conservation
and application, and may include subjects with clinical complica-
tions that could compromise their immune response. Accordingly,
the rate of seroconversion following routine vaccination in military
personnel in this study has been reported to be slightly lower than
that in healthy volunteers in controlled studies [15]. In addition, a
weaker immune response can result in shorter immunity duration.
Cut-off values correlating with protection are not available
for antibody titres measured by serum-dilution plaque-reduction
tests. As in several previous studies, we  analysed seropositivity
as a convenient, but possibly exagerated proxy of protection. On
the other hand, antibody titres are important indicators of the
occurrence of immunological memory and may  indicate a direct
association between positive serology and immune protection.
Therefore, a complete assessment of the immunological memory
must include components of the cellular immune system, which
are crucial for cytotoxic responses and the effective production of
neutralising antibodies [11].
Considering the absence of herd immunity during the sylvatic
cycle of yellow fever, immunisation programmes need to effec-
tively reach all individuals at risk because viral circulation occurs
independently of human hosts. In sub-Saharan Africa, where yel-
low fever outbreaks result from the urban transmission cycle,
herd immunity assumes that the vaccination coverage should be
homogeneous to avoid the occurrence of outbreaks in susceptible
population groups. SAGE also indicated in the position paper [4]
that surveillance data and clinical studies can identify speciﬁc risk
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roups, such as infants and HIV-infected individuals, who could
eneﬁt from a second immunisation or a booster dose. In South
merican countries, where yellow fever vaccination is routinely
dministered during the ﬁrst year of life, and in African countries,
here the risk of yellow fever and the high prevalence of HIV
nfection coexist, a second immunisation or a booster dose might
herefore be indicated, consistent with evidence suggesting that
hose subgroups appear to mount less intense responses after vac-
ination [7].
In conclusion, serological data from this and other studies may
ndicate the need to anticipate revaccination, considering that
he percentage of seronegative subjects is high at 5 years post-
accination, and the performance of serological tests to select
ubjects in need of revaccination is not recommended as a public
ealth measure. The recommendation to abolish subsequent vac-
ination every 10 years would appear safer if the administration
f 2 doses is adopted in endemic areas, particularly those where
rimovaccination is routinely performed in children under 2 years
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